Pharma Focus Europe

Fibrocor Therapeutics and McQuade Center for Strategic Research and Development Partner to Advance Alport Syndrome Program

Wednesday, March 06, 2024

Fibrocor Therapeutics Inc., a leader in developing innovative treatments for fibrosis, has established a research and development collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD) to advance its Alport Syndrome program. The partnership entails a substantial upfront payment in the single-digit million-dollar range, with additional funding potentially covering Phase 1b studies. MSRD, affiliated with the Otsuka family of pharmaceutical companies, focuses on identifying and nurturing early-stage opportunities aimed at transforming treatments for mental illness and renal disorders.

FIB918 is currently progressing through the crucial IND-enabling phase, with Phase 1 clinical trials for the monoclonal antibody expected to begin in late 2025. Fibrocor and MSRD will collaborate closely with patients, advocacy groups, and regulatory bodies to ensure the execution of safe, effective, and inclusive clinical trials, considering patient input and lifestyle factors, with the goal of positively reshaping the clinical landscape and treatment approach for Alport Syndrome patients.

William P. Newsome III, CEO and President of Fibrocor, expressed enthusiasm about the collaboration, stating, "This partnership with the seasoned team at MSRD, combined with substantial research funding, underscores the validation of Fibrocor's cutting-edge target discovery platform. It offers hope and potential for individuals worldwide grappling with Alport Syndrome. FIB918 holds promise for delivering a significant advancement in treating patients afflicted by this debilitating disease, where current treatment options are limited. Achieving our Investigational New Drug (IND) application milestone and the anticipated launch of clinical trials in 2025 represent pivotal moments in our quest to make a meaningful difference in the lives of those affected by Alport Syndrome."

Piet Wigerinck, Chief Scientific Advisor of Fibrocor, commented, "This collaboration further validates our platform, bringing together dedicated teams backed by world-class experts and substantial resources. It drives our ongoing commitment to advancing our small molecule program, with FIB992 poised to enter clinical trials later this year for idiopathic pulmonary fibrosis (IPF), another devastating, underserved fibrotic disease. Following this, clinical trials for FIB991 for chronic allograft nephropathy are scheduled to commence in 2025. We remain steadfast in our dedication to making a meaningful impact on patients grappling with fibrotic diseases, and eagerly anticipate a fruitful collaboration with our MSRD counterparts."

Alport Syndrome is a rare form of kidney inflammation caused by specific gene mutations, resulting in structural defects, renal fibrosis, and kidney failure. It is estimated that about one in 50,000 individuals suffer from this condition, although estimates vary. Most patients experience kidney failure in young adulthood or middle age.

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal disease characterized by lung scarring that thickens the lung lining, leading to irreversible impairment of oxygen transport. Ultimately, IPF deprives patients of their ability to breathe, with reported median survival ranging from two to five years.

 

Source: prnewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva